Cardiovascular
Skajaa N, Adelborg K, Horvath-Puho E, Rothman KJ, Henderson VW, Thygesen LC, Sorensen HT. Nationwide trends in incidence and mortality of stroke among younger and older adults in Denmark. Neurology. 2021 Mar 30;96(13):e1711-23. doi: 10.1212/WNL.0000000000011636
OBJECTIVE: To investigate the extent to which the incidence and mortality of a first-time stroke among younger and older adults changed from 2005 to 2018 in Denmark using nationwide registries.
Mody R, Meyers J, Yu M, Levine J, Davis KL. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the U.S. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Wu B, Morland K, Classi P, Sketch MR, Nelson A, Goyal RK, Davis KL, Oudiz R. Economic burden of patients with pulmonary arterial hypertension prior to initiation of treprostinil: a retrospective analysis of US claims. Poster presented at the ATS International 2021 Conference; May 14, 2021.
Mangel A, Lothman K, Mangel TP. Pulse synchronized contractions: a review. EC Cardiology. 2020 Jul 29;7(8):61-6.
Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
OBJECTIVES: To develop a robust and clinically relevant economic model to assess cost-effectiveness of a novel oral treatment in LDL-C lowering in a universe of generic statins and ezetimibe and restricted-access PCSK9 inhibitors.
Requena G, Ma L, Sturmer T, Layton JB, DiBello J. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Invest. 2020 Aug;40:747-54. doi: 10.1007/s40261-020-00935-1
BACKGROUND AND OBJECTIVE: The literature describing the long-term effect of an acute, drug-induced decrease in high-density lipoprotein cholesterol (HDL-C) and cardiovascular (CV) risk is limited. We aimed to further explore this potential association.
Ruigomez A, Plana E, Gilsenan A, Fortuny J, Cainzos-Achirica M, Flynn RWV, MacDonald TM, Garcia-Rodriguez L, Ziemiecki R, Andrews EB. Identification and validation of major cardiovascular events in the United Kingdom data sources included in a multi-database post-authorization safety study of prucalopride. Drug Saf. 2021 May;44(5):541-51. doi: 10.1007/s40264-021-01044-4
Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371
OBJECTIVES: To estimate T2DM and CV-related health care resource utilization (HCRU) and costs among patients with T2DM and cardiovascular disease (CVD; e.g., stroke) or CV risk factors (CV risk; e.g., hypertension) in the United States.
Fortuny J, Agusti A. Secondary prevention of acute myocardial infarction: should oral anticoagulants and platelet antiaggregants be administered on a combined basis? Med Clin (Barc). 2003 Oct 4;121(11):433-5. doi: 10.1016 / S0025-7753 (03) 73977-3
Abstract not available at this time.